EAM Investors’s Protalix BioTherapeutics PLX Stock Holding History

EAM Investors’s Portfolio PLX Stock Details PLX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-165,631	Closed	-$331K	–	359
2023 Q2	$331K	Buy	+165,631	New	+$395K	0.06%	256

Other funds holding PLX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

GCP

GSA Capital Partners London, United Kingdom $1.61B AUM 28.28% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

EAM Investors's PLX Position: Q3 2023 in Review

EAM Investors sold out of Protalix BioTherapeutics (PLX) in Q3 2023, closing a stake of 165,631 shares — an estimated $331K sold.

EAM Investors first reported a position in PLX in Q2 2023 and held it in 1 quarter. The position peaked at $331K in Q2 2023. 61 funds tracked by Wall St. Rank hold PLX as of Q3 2023.

EAM Investors reported no remaining Protalix BioTherapeutics position as of Q3 2023 after selling out during the quarter.
EAM Investors sold 165,631 Protalix BioTherapeutics shares in Q3 2023, an estimated $331K.
EAM Investors first reported a position in Protalix BioTherapeutics in Q2 2023 and held it in 1 quarter.
EAM Investors's Protalix BioTherapeutics position peaked at $331K in Q2 2023.
61 funds tracked by Wall St. Rank held Protalix BioTherapeutics as of Q3 2023.

Based on EAM Investors's 13F filing for Q3 2023, filed 13 Nov 2023.